Inhibitors of cyclin-dependent kinases as cancer therapeutics.


Over the past two decades there has been a great deal of interest in the development of inhibitors of the cyclin-dependent kinases (CDKs). This attention initially stemmed from observations that different CDK isoforms have key roles in cancer cell proliferation through loss of regulation of the cell cycle, a hallmark feature of cancer. CDKs have now been… (More)
DOI: 10.1016/j.pharmthera.2017.02.008


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.